Holen Sie sich die Stockscreener-App
15.28
3.24%
0.461
Schlusskurs vom Vortag:
$14.82
Offen:
$14.9
24-Stunden-Volumen:
293.96K
Relative Volume:
0.23
Marktkapitalisierung:
$1.49B
Einnahmen:
$221.08M
Nettoeinkommen (Verlust:
$-2.92M
KGV:
305.62
EPS:
0.05
Netto-Cashflow:
$5.89M
1W Leistung:
+11.76%
1M Leistung:
+36.24%
6M Leistung:
+81.93%
1J Leistung:
-5.38%
1-Tages-Spanne:
$14.85
$15.39
1-Wochen-Bereich:
$13.40
$15.39
52-Wochen-Spanne:
$6.38
$16.66
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Firmenname
Avadel Pharmaceuticals Plc
Sektor
Telefon
636-449-1830
Adresse
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Vergleichen Sie AVDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
15.34 | 1.31B | 221.08M | -2.92M | 5.89M | 0.05 |
|
ZTS
Zoetis Inc
|
157.12 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.47 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.875 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.86 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.94 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-05 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-05 | Bestätigt | Needham | Buy |
| 2024-03-05 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2022-11-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-28 | Fortgesetzt | Craig Hallum | Buy |
| 2022-05-26 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-03 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Eingeleitet | Stifel | Buy |
| 2020-02-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-30 | Eingeleitet | Craig Hallum | Buy |
| 2019-06-14 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-02-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
Alle ansehen
Avadel Pharmaceuticals Plc Aktie (AVDL) Neueste Nachrichten
Earnings call transcript: Avadel Pharmaceuticals beats Q2 2025 expectations - Investing.com
Avadel Pharmaceuticals plc Attempts Reversal From Key SupportPortfolio Value Summary & Reliable Entry Point Alerts - mustnews.co.kr
Are Options Traders Betting on a Big Move in Avadel Pharmaceuticals Stock? - Yahoo Finance
Can Avadel Pharmaceuticals plc Escape Recent Bear ChannelEarnings Recap Report & Free Weekly Watchlist of Top Performers - beatles.ru
Avadel Pharmaceuticals (NASDAQ:AVDL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Avadel (AVDL) Q2 Revenue Jumps 64% - AOL.com
Avadel Pharmaceuticals Plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - 富途牛牛
Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know - Zacks Investment Research
Avadel Pharmaceuticals Plc (NASDAQ:AVDL) Has Found A Path To Profitability - 富途牛牛
Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Avadel Pharmaceuticals plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Yahoo Finance
Craig-Hallum Maintains Buy Rating for Avadel Pharmaceuticals with $18 Price Target - AInvest
Avadel Pharmaceuticals Q2 2025 Earnings Call Transcript: Forward-Looking Statements and Risks - AInvest
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2025 Earnings Call Transcript - Insider Monkey
Avadel Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Avadel raises 2025 revenue guidance to $275M as LUMRYZ patient base grows 63% year-over-year - MSN
Avadel Pharmaceuticals shares fall 2.43% intraday after announcing inducement awards. - AInvest
Avadel Pharmaceuticals stock price target raised to $24 at H.C. Wainwright - Investing.com Nigeria
Avadel Pharmaceuticals: HC Wainwright Raises Buy Rating, PT to $24 - AInvest
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Avadel Pharmaceuticals PLC (AVDL) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Avadel Pharmaceuticals Raises 2025 Revenue Guidance to $275M Amid 63% YoY Growth in LUMRYZ Patient Base - AInvest
Avadel Pharmaceuticals Reports Strong Q2 Growth - TipRanks
Avadel: Q2 Earnings Snapshot - The Washington Post
Avadel Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView
AVADEL PHARMACEUTICALS PLC SEC 10-Q Report - TradingView
Avadel Pharma earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Avadel Pharma Q2 revenue up 64%, raises 2025 guidance - MarketScreener
Earnings Flash (AVDL) Avadel Pharmaceuticals Posts Q2 EPS $0.10, vs. FactSet Est of $0.03 - MarketScreener
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView
Avadel raises FY25 revenue guidance to $265-$275 mln after Q2 net rev. of $68.1 mln. - AInvest
Avadel Q2 rev up 64% to $68.1mln, raises FY25 guidance to $265-$275mln. - AInvest
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance - The Manila Times
Avadel Earnings: Revenue Soars 64%, Reports First Profit Since LUMRYZ Launch, Boosts 2025 Outlook - Stock Titan
Avadel Pharmaceuticals PLC expected to post earnings of 3 cents a shareEarnings Preview - TradingView
Avadel Pharmaceuticals plc Volume Confirms Breakout — Analysts BullishSwing Trading Plan With Smart Signals in Review - beatles.ru
What catalysts could drive Avadel Pharmaceuticals plc stock higher in 2025Discover undervalued opportunities early - Jammu Links News
What is the risk reward ratio of investing in Avadel Pharmaceuticals plc stockUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Avadel Pharmaceuticals plc stockSuperior investment outcomes - Jammu Links News
What analysts say about Avadel Pharmaceuticals plc stockUnprecedented growth rates - Jammu Links News
What is Avadel Pharmaceuticals plc company’s growth strategyBoost your returns with professional guidance - Jammu Links News
How many analysts rate Avadel Pharmaceuticals plc as a “Buy”Superior profit margins - Jammu Links News
How does Avadel Pharmaceuticals plc compare to its industry peersHigh-yield capital appreciation - Jammu Links News
Is Avadel Pharmaceuticals plc a good long term investmentFree Predictions - Jammu Links News
When is Avadel Pharmaceuticals plc stock expected to show significant growthOutperformance with explosive growth - Jammu Links News
How volatile is Avadel Pharmaceuticals plc stock compared to the marketCapitalize on emerging growth stocks - Jammu Links News
What are the latest earnings results for Avadel Pharmaceuticals plcInvest in stocks with strong fundamentals - Jammu Links News
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb - simplywall.st
Finanzdaten der Avadel Pharmaceuticals Plc-Aktie (AVDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avadel Pharmaceuticals Plc-Aktie (AVDL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thornton Peter J. | Director |
Jan 13 '25 |
Buy |
8.04 |
10,000 |
80,450 |
104,055 |
| Ende Eric J | Director |
Jan 13 '25 |
Buy |
7.84 |
30,000 |
235,218 |
208,900 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 13 '24 |
Buy |
10.44 |
2,300 |
24,019 |
87,800 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 11 '24 |
Buy |
10.49 |
5,000 |
52,432 |
85,500 |
| Divis Gregory J | Chief Executive Officer |
Dec 06 '24 |
Buy |
9.98 |
9,598 |
95,759 |
9,598 |
| Divis Gregory J | Chief Executive Officer |
Dec 09 '24 |
Buy |
9.82 |
402 |
3,948 |
10,000 |
| Glass Geoffrey Michael | Director |
Dec 10 '24 |
Buy |
9.84 |
20,279 |
199,641 |
75,904 |
| Palczuk Linda | Director |
Dec 06 '24 |
Buy |
10.19 |
3,000 |
30,568 |
66,400 |
0.46%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):